Inhibition of the renin-angiotensin system in diabetic patients – beyond HOPE

Br J Cardiol 2004;11:123-27 Leave a comment
Click any image to enlarge
Authors:

Treatment to reduce blood pressure is effective in preventing and slowing the progression of the vascular complications of diabetes. Recent studies have suggested that use of antihypertensives that inhibit the renin-angiotensin system may have particular benefit in patients with type 2 diabetes in terms of cardiovascular and renal protection. Present practice is to use angiotensin-converting enzyme (ACE) inhibitors as first-line agents, with angiotensin II receptor antagonists (AIIAs) as back-up drugs in the event of side effects or intolerance. The findings of recent trials with AIIAs, however, suggest that they are an equivalent class of drugs to the ACE inhibitors from the point of view of renal profile and that their better side-effect profile could also make them suitable first-line drugs for patients with microalbuminuria and overt nephropathy.

Advertisement
Angina - BJC Learning programme
For healthcare professionals only

THERE ARE CURRENTLY NO COMMENTS FOR THIS ARTICLE - LEAVE A COMMENT